中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.016 seconds)

    IMMUNOASSAY OF S-ADENOSYLMETHIONINE USING ANALOGS THEREOF AND PERSONALIZED THERAPEUTICS
    1.
    发明申请
    IMMUNOASSAY OF S-ADENOSYLMETHIONINE USING ANALOGS THEREOF AND PERSONALIZED THERAPEUTICS 审中-公开

    公开(公告)号：US20180169128A1

    公开(公告)日：2018-06-21

    申请号：US15881817

    申请日：2018-01-29

    Applicant: Xiujuan Hao ,  Isaac Angres

    Inventor： Xiujuan Hao ,  Isaac Angres

    IPC: A61K31/7076 ,  G01N33/574

    CPC classification number: A61K31/7076 ,  G01N33/57484 ,  G01N2800/7033

    Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.

    IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    5.
    发明申请
    IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY 审中-公开
    鉴定需要PD-L1抑制剂COEPAPY的患者

    公开(公告)号：US20160333414A1

    公开(公告)日：2016-11-17

    申请号：US14720643

    申请日：2015-05-22

    Applicant: HOFFMANN-LA ROCHE INC.

    Inventor： Anton BELOUSOV ,  Giampaolo BIANCHINI ,  Luca GIANNI ,  Marlene THOMAS

    IPC: C12Q1/68 ,  G01N33/68 ,  G01N33/574 ,  G01N33/74 ,  A61K39/395 ,  A61K31/337

    CPC classification number: C12Q1/6886 ,  A61K31/337 ,  A61K39/39558 ,  A61K2039/505 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/6866 ,  G01N33/6872 ,  G01N33/743 ,  G01N2333/57 ,  G01N2333/70532 ,  G01N2333/723 ,  G01N2800/7033

    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.

    Abstract translation: 本发明涉及用于确定患者是否需要PD-L1抑制剂治疗的方法和方法。 如果在体外测量与对照相比增加的程序性死亡配体1（PD-L1）的低或不存在的ER表达水平和程序性死亡配体1（PD-L1）的表达水平，则确定患者需要PD-L1抑制剂治疗 来自病人的样本。 患者正在接受治疗，其包括HER2 / neu（ErbB2）信号传导途径的调节剂（如曲妥珠单抗）和化学治疗剂（如十二赛酚）），或者为患者预期这样的治疗。 本文还提供了用于治疗癌症患者的癌症的方法和方法，所述癌症患者包括HER2 / neu（ErbB2）信号传导途径的调节剂（如曲妥珠单抗）和化学治疗剂（如十二赛酚）），其中患者是 接受PD-L1抑制剂治疗。

    Method of using disposable BioMEMS coagulation profiling cartridge
    6.
    发明授权
    Method of using disposable BioMEMS coagulation profiling cartridge 有权

    公开(公告)号：US11788941B1

    公开(公告)日：2023-10-17

    申请号：US17087518

    申请日：2020-11-02

    Applicant: iFirst Medical Technologies, Inc.

    Inventor： Luke B. Joseph ,  Thomas A. Hasling

    IPC: G01N33/86 ,  G01N11/14 ,  B01L3/00

    CPC classification number: G01N11/14 ,  B01L3/502 ,  G01N33/86 ,  B01L2300/041 ,  B01L2300/0803 ,  B01L2300/0848 ,  B01L2400/043 ,  G01N2011/147 ,  G01N2800/224 ,  G01N2800/7033

    Abstract: A handheld medical analyzer works with different disposable application cartridges to perform a variety of interrogations on specimen samples. One application includes attaching a biological microelectromechanical systems (BioMEMS) cartridge that generates blood coagulation profiles indicative of particular forms of coagulation disorders. The device makes coagulopathy testing simpler for small hospitals, clinics, ambulances, remote locations and individuals and permits for a larger number of parallel or serial devices operating simultaneously. One insertion of a cartridge actuates an oscillating circular motion to generate a blood coagulation profile based on a change in rotational motion as blood coagulates in a sample. Change in rotational motion is analyzed through a video camera such as in a smartphone and is plotted to show an amplitude over time. Actuation of the BioMEMS can be achieved by magnetic actuation of a motor controlled by an iPhone or a smart phone to provide a specific rotational pattern.

    ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH
    10.
    发明申请
    ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH 审中-公开

    公开(公告)号：US20170192014A1

    公开(公告)日：2017-07-06

    申请号：US15127644

    申请日：2015-03-20

    Applicant: WELLSTAT DIAGNOSTICS ,llc

    Inventor： Jeffrey Allan MILLER ,  Eddie Phillip JEFFRIES

    IPC: G01N33/68 ,  C07K16/18

    CPC classification number: G01N33/6893 ,  C07K16/18 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/72 ,  G01N33/54333 ,  G01N2333/4742 ,  G01N2510/00 ,  G01N2800/085 ,  G01N2800/7033

    Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK1 8 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

Patent Agency Ranking